Breast Cancer - Pipeline Review, H2 2016
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides an overview of the Breast Cancer (Oncology) pipeline landscape.
Breast cancer is a cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. Risk factors of breast cancer includes age, beginning of periods before the age of twelve or going through menopause after the age of fifty-five, being overweight, using hormone replacement therapy, consumption of birth control pills and consumption of alcohol. Symptoms include a lump in the breast, a change in size or shape of the breast or discharge from a nipple. Treatment includes radiation, lumpectomy, mastectomy, chemotherapy and hormone therapy.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Breast Cancer – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Breast Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Breast Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Breast Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 12, 45, 158, 167, 2, 13, 474, 96 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 16, 17, 1, 150 and 44 molecules, respectively.
Breast Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.